A Clinical Masterclass: LEQVIO in Clinical Practice
Welcome to the Novartis microsite for the Cardiac Society of Australia and New Zealand (CSANZ) Congress, held in Adelaide on 3-6 August 2023.
Watch the full recording of "A clinical masterclass: LEQVIO in Clinical Practice"
The content of this page is provided for the purpose of medical education only, and may include information on unregistered products or off-label topics. Please review the Australian Product Information before prescribing, available at www.tga.gov.au. The views expressed are those of the speakers and do not necessarily reflect those of Novartis.
Medical Information Service
Medical Enquires, Information services, Adverse Events and Product Complaints please contact:
Telephone: 1800 671 203
Mail: [email protected]
Colleagues are available from 9:00 to 17:00 from Monday to Friday
Please review Product Information before prescribing available at www.novartis.com/au-en/products/healthcare-professionals. For medical enquiries please contact 1800 671 203.
PBS Information: This product is not listed on the PBS.
▼ This medicinal product is subject to additional monitoring in Australia due to provisional approval. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.
See approved Leqvio Product Information before prescribing. For the most up to date Product Information click here.
LEQVIO® and the LEQVIO® logo are registered trademarks of Novartis AG. Licensed from Alnylam Pharmaceuticals, Inc.
Novartis Pharmaceuticals Australia Pty Limited. ABN 18 004 244 160. 54 Waterloo Road, Macquarie Park, NSW 2113. ©2023 Novartis Pharmaceuticals Australia Pty Limited.